Brexpiprazole

From WikiMD's WELLNESSPEDIA

Brexpiprazole
Brexpiprazole molecule ball

Atypical antipsychotic medication

Brexpiprazole

Brexpiprazole


Trade names Rexulti


Chemical nomenclature
IUPAC name 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]quinolin-2(1H)-one



Routes Oral







Identifiers
CAS Number 913611-97-9
PubChem 11978813
DrugBank DB09128
ChemSpider 10106341
UNII 4D3O70HQHF
KEGG D10300
ChEMBL 2105710
Chemical data


Chemical formula C25H27N3O2S1






Brexpiprazole is an atypical antipsychotic medication used primarily in the treatment of schizophrenia and as an adjunctive therapy for major depressive disorder. It is marketed under the brand name Rexulti.

Medical uses[edit]

Brexpiprazole is indicated for the treatment of schizophrenia and as an adjunctive treatment for major depressive disorder (MDD). It is also being studied for the treatment of agitation associated with dementia of the Alzheimer's type.

Mechanism of action[edit]

Brexpiprazole acts as a serotonin-dopamine activity modulator (SDAM). It is a partial agonist at 5-HT1A and D2 receptors and an antagonist at 5-HT2A receptors. This unique mechanism of action is thought to contribute to its efficacy in treating both psychotic and mood disorders.

Side effects[edit]

Common side effects of brexpiprazole include weight gain, akathisia, and headache. Less common but more serious side effects can include tardive dyskinesia, neuroleptic malignant syndrome, and hyperglycemia.

Pharmacokinetics[edit]

Brexpiprazole is administered orally. It has a half-life of approximately 91 hours, allowing for once-daily dosing. The drug is metabolized primarily by the cytochrome P450 enzymes CYP3A4 and CYP2D6.

History[edit]

Brexpiprazole was developed by Otsuka Pharmaceutical and Lundbeck. It was approved by the U.S. Food and Drug Administration (FDA) in July 2015 for the treatment of schizophrenia and as an adjunctive treatment for major depressive disorder.

See also[edit]

References[edit]


External links[edit]

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.


Brexpiprazole[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Brexpiprazole&oldid=6620260"